Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	5/31/2006 9:18:07 PM
	Read Replies (1) of 3044

A bit of somewhat unexpected good news. Have all MLNM's fan deserted it??? 08:02 ET Millennium Pharm announces MLN1202 fully met primary endpoint in Phase II clinical study of patients at high Rrsk for atherosclerosis (MLNM) 8.14 :Co announces positive top-line results from the co's randomized, double-blinded, placebo-controlled Phase II clinical trial of MLN1202, a novel humanized monoclonal antibody that specifically targets the CCR2 chemokine receptor, in patients at high risk for atherosclerotic cardiovascular disease. Preliminary analysis showed that MLN1202 was well tolerated and fully met its primary endpoint of a significant reduction in C-Reactive Protein levels, an inflammatory biomarker associated with atherosclerosis, for months after a single dose of MLN1202. These results were statistically and clinically significant relative to the placebo control arm. No serious adverse events were observed in patients exposed to MLN1202. Trial results are expected to be submitted for presentation at a medical meeting.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next